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Abstract
Heat-shock protein 90 (Hsp90) inhibitors exhibit activity against human cancers. We evaluated a series of new, oral
bioavailable, chemically diverse Hsp90 inhibitors (PU-H71, AUY922, BIIB021, NVP-BEP800) against Kaposi sarcoma (KS). All
Hsp90 inhibitors exhibited nanomolar EC50 in culture and AUY922 reduced tumor burden in a xenograft model of KS. KS is
associated with KS-associated herpesvirus (KSHV). We identified the viral latency associated nuclear antigen (LANA) as a
novel client protein of Hsp90 and demonstrate that the Hsp90 inhibitors diminish the level of LANA through proteasomal
degradation. These Hsp90 inhibitors also downregulated EphA2 and ephrin-B2 protein levels. LANA is essential for viral
maintenance and EphA2 has recently been shown to facilitate KSHV infection; which in turn feeds latent persistence.
Further, both molecules are required for KS tumor formation and both were downregulated in response to Hsp90 inhibitors.
This provides a rationale for clinical testing of Hsp90 inhibitors in KSHV-associated cancers and in the eradication of latent
KSHV reservoirs.
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Introduction
Heat shock protein 90 (Hsp90) is a conserved molecular
chaperone that facilitates the maturation of a wide range of
proteins and assists in the correct folding and productive assembly
of cellular proteins and multimeric protein complexes in normally
growing cells [1,2]. Hsp90 also has important roles in maintaining
the transformed phenotype of cancer cells. Overexpression of
Hsp90 has been detected in a variety of cancers [3,4,5]. Hsp90 is
required for proper folding of its ‘‘client proteins’’ many of which
are effectors of key signal transduction pathways controlling cell
growth, differentiation, the DNA-damage response, and cell
survival [6]. Cancer cells are critically addicted to the Hsp90
chaperone machinery whose activity protects an array of mutated
and overexpressed oncoproteins, and other cellular client proteins
from misfolding and degradation [7,8].
Hsp90 is an emerging therapeutic target for cancer [8,9,10].
The newer class of Hsp90 inhibitors bind to the ATP-binding
motif of Hsp90 and inhibit its protein chaperoning activity,
resulting in misfolding, subsequent degradation of cellular client
proteins, and ultimately tumor cell death [4,7,11,12]. Hsp90
inhibitors are selective for tumor cells because the chaperoning
function of Hsp90 is required for most tumor cells. Even though
the new inhibitors are highly selective for Hsp90, Hsp90 has many
client proteins, each of which can contribute to the transformed
phenotype. For instance, Hsp90 is involved in NFkB activation by
IKK [13] in normal and lymphoma cells, including in the Kaposi
sarcoma-associated herpesvirus (KSHV) driven lymphoma cell
lines [14,15]. Additionally, soluble extracellular Hsp90 has been
implicated in supporting de novo infection by KSHV [16].
We focused our attention on (i) ephrins and ephrin receptors
because of their connection to Kaposi sarcoma (KS) and Kaposi
sarcoma associated herpesvirus (KSHV) infection and (ii) on the
KSHV latency associated nuclear antigen (LANA), which is
essential for maintaining the KSHV virus and thereby the
transformed phenotype [17]. Kaposi sarcoma (KS) is an endothe-
lial cell lineage cancer; in fact, KS is one of the most vascular
human cancers.
Ephrin interactions can trigger a wide array of cellular
responses, including cell adhesion, boundary formation and
repulsion [18]. Ephrin-A1 for instance was discovered as a TNF-
inducible protein in HUVEC cells. Ephrins are membrane bound
by glycosylphosphatidylinositol (GPI) anchor in case of ephrin-A1
to A5 and a transmembrane domain in case of ephrin-B1 to B5.
They form receptor ligand pairs with ephrin receptors.
Ephrin-B2 plays critical roles in vessel maturation. It is
expressed on endothelial cells, arterial angioblasts and perivascular
mesenchymal cells. Ephrin-B2 is expressed at substantial levels in
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KS, KS cell lines, transformed lymphatic endothelial cells (LEC/
HHV-8), and in KS tissue [19,20]. The continued presence of
KSHV and expression of viral proteins are essential for the
development of KS, and KSHV can reprogram primary
endothelial cells to extend their life-span and to acquire features
of transformation [21,22,23,24,25,26,27]. Ephrin-B2 signals
through the EphB4 receptor.
EphA2 is a receptor for ephrin-A1 [28]. Ephrin receptors are
receptor tyrosine kinases. EphA2 has previously been identified as
an Hsp90 client protein [29,30]. It is overexpressed in a large
number of human malignancies and supports tumor angiogenesis
[29,30]. Targeting the ephrin-ephrin receptor interactions by
antibodies, siRNA, or soluble ligands (e.g soluble EphB4, the
receptor for ephrin-B2, fused to albumin [31]) disrupts endothelial
cell function and tumor vasculature [32,33]. The first clinical
studies targeting ephrin interactions are currently in design. This
establishes ephrins as key regulators of tumor angiogenesis and
endothelial cell growth.
EphA2 also has a newly identified direct role in KSHV infection
of endothelial cells. EphA2 has been established as a co-receptor of
KSHV, binding to the viral gH and gL proteins [34], and as a
mediator of KSHV-induced signaling [35]. Because initial
infection of endothelial cells with KSHV is a prerequisite for
them to eventually become KS tumor cells, and because periodic
re-infection seems to contribute to viral maintenance and tumor
progression, any drug that interferes with latency (via targeting
LANA) and lowers re-infection (via targeting ephrin) would
significantly impact KS pathogenesis.
Like other herpesviruses, KSHV exhibits two distinct phases in
its life cycle, latent and lytic replication. During latent infection,
only a small subset of viral proteins is expressed in the KS tumor
cells chiefly the latency-associated nuclear antigen (LANA)
[36,37]. LANA is necessary and sufficient for episome persistence
of KSHV [38]; it is required for tumor cell survival [17]. LANA
can interact with a multitude of partners [39,40,41,42,43],
including tumor suppressor proteins, leading to the inhibition of
apoptosis and dysregulation of the cell cycle [44,45,46]. These
activities contribute to tumor cell survival and cell proliferation.
Thus viral latent proteins constitute a highly specific target for KS
cancer therapy.
In the present work, we discovered that Hsp90 is an essential
regulator of LANA, ephA2 and ephrin-B2. Multiple, highly
specific, chemically distinct and oral bioavailable Hsp90 inhibitors
were used to treat PEL and KS tumor lines. This accelerated the
degradation of LANA through the proteasomal pathway and
downregulated ephrin B2 levels. The result was growth inhibition
in culture at nanomolar concentrations, and tumor retardation in
a xenograft model of KS.
Materials and Methods
Cell culture, antibodies and drugs
BJAB, BJAB-LANA derivatives and the KSHV positive PEL
cell lines BC-3, BCP-1, BCBL-1, and BC-1 were cultured in
RPMI 1640 medium (Cellgro) containing 2 mM L-glutamine,
10% fetal bovine serum, penicillin G (100 U/ml) and streptomy-
cin sulfate (100 mg/ml) and supplemented with 0.05 mM 2-
mercaptoethanol (Sigma), 0.075% sodium bicarbonate (Life
Technologies), and 1 U/ml human interleukin-6 (IL-6) (Roche).
SLK, SLK-KSHV, L1T2, TIVE-L1, KS-IMM and HeLa cell
lines were cultured in DMEM (Cellgro) supplemented with
100 mg/ml streptomycin, 100 U/ml penicillin G (Life Technolo-
gies, Carlsbad, CA, USA), and 10% FBS at 37uC in 5% CO2.
SLK-KSHV cells (gift of Dr. Don Ganem [47]) were maintained
with additional puromycin (1 mg/ml, Invitrogen).
Rat anti-LANA monoclonal LN53 was purchased from
Advanced Biotechnology Inc., anti-LANA polyclonal rabbit
antiserum YT041 was raised again the LANA repeat region
[48], and mouse anti-LANA (13B10) was from Leica Biosystems
Newcastle Ltd. Rabbit cleaved PARP (Asp214, D64E10), Cleaved
caspase-3 (Asp175, 5A1E), rabbit Anti-Akt and phospho-Akt
(Ser473, D9E) were purchased from Cell Signaling. Mouse Anti-b-
Actin, mouse anti-hemagglutinin (anti-HA, clone HA-7) and
mouse anti-FLAG (clone M2) antibodies were purchased from
Sigma Inc. Anti-ephrin B2 antibody was purchased from R&D
Systems (catalog number: AF496, Minneapolis, MN). Mouse anti-
Cdc-2 p34 (17, sc-54) and rabbit anti-EphA2 (C-20, sc-924)
antibodies were from Santa Cruz. Mouse anti-Hsp90b (SPA-842)
and anti-Hsp90 (Ab1429) antibodies were purchased from
Stressgen and Abcam Inc, respectively. Hsp90 inhibitor 17-
DMAG was from Invivogen Inc.; and PU-H71 from Sigma Inc..
BIIB021, NVP-AUY922 and NVP-BEP800 were purchased from
Selleck.
MS/MS analysis for LANA complexes
FLAG-tagged LANA (kindly provided by Dr. Ken Kaye [42])
was cloned into pcDNA3 to yield pDD1946 (aa1–1162). Flag-HA-
double tagged central-repeat deleted (1-329+928-1162aa) expres-
sion construct was cloned into pcDNA3 to yield pDD1945 as
follows: The central repeat LANA mutant pMF-24 was kindly
provided by Dr. Diane Hayward [45]. Both tagged LANA
mutants were transfected into BJAB cells with lipofectamin 2000
(Invitrogen). Stable BJAB cells were selected with G-418 (1 mg/
ml, Gibco). Approximately 56109 cells were harvested after large-
scale culture. Nuclear extraction of BJAB (FLAG-LANA) cells was
performed as previously described, followed by two chromato-
graphic columns of Sepharose 6B and Heparin FF [48]. Isolated
samples from chromatographic columns were further purified by
another two-step immunoaffinity method, first by incubation with
50 ml EZ view anti-FLAG M2 affinity resin (Sigma) in TBS
(10 mM Tris-HCl, 100 mM NaCl [pH 8.0]) overnight at 4uC,
then the FLAG-tagged protein was eluted by 200 ml of 150 mg/ml
36FLAG peptide (Sigma), washed three times and diluted with
cold RIPA buffer (150 mM 150 mM NaCl, 0.5% NP-40, 50 mM
Tris-HCl [pH 8.0], 1 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF,
0.5% cocktail protein inhibitor (Sigma)). Finally, rat anti-LANA
Author Summary
Heat shock proteins, such as Hsp90, aid the folding of
proteins. They seem to be essential to sustain the growth
of cancer cells. Hsp90 inhibitors are in clinical trials for
many cancers but with mixed results, presumably since
these proteins have many clients. The mechanism for drug
efficacy and tumor-type variation in responses is not
understood. Here we show that in the case of Kaposi
sarcoma and primary effusion lymphoma, which are
cancers caused by Kaposi sarcoma associated herpesvirus
(KSHV/HHV8) an essential viral protein, LANA, binds to
Hsp90 and is a client of Hsp90. Different small molecule
Hsp90 inhibitors reduce the expression of LANA. At the
same time they reduce the expression of the newly
discovered co-receptor of KSHV ephA2, of Akt, cdc2 and
ephrin-B2. Since LANA is required to maintain the virus
latent in all tumor cells, a process, which is periodically
aided by de novo infection, these inhibitors interfere with
essential components of viral pathogenesis and in vivo
tumor growth.
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(clone LN53) or mouse anti-HA (clone HA-7) was used for further
purification of LANA complexes, rat IgG was used for control
(Sigma). Purified proteins were resolved by 8 to 16% gradient
SDS-PAGE and stained with colloidal blue (Invitrogen). Visible
bands were cut and further subjected to mass spectrometry at the
University of North Carolina—Chapel Hill core facility.
Immunoprecipitation and Western blotting
A series of full length or FLAG-LANA mutant expressing
plasmids (pDD1928 (aa1–329), pDD1931 (aa930–1162) and
pDD775) were obtained from Dr. Diane Hayward [45,49]. These
together with HA-Hsp90 [50] were co-transfected separately into
HeLa cells and harvested after 48 hours. Mab mouse anti-HA and
anti-FLAG were used in immunoprecipitation assay as previously
described [48]; mouse IgG was used as control. Samples were
washed with cold RIPA buffer (150 mM 150 mM NaCl, 0.5%
NP-40, 50 mM Tris-HCl [pH 8.0], 1 mM EDTA, 0.5 mM DTT,
0.5 mM PMSF, 0.5% cocktail protein inhibitor), followed by SDS-
PAGE analysis and transferred into Hybond P membranes
(Amersham), secondary antibodies conjugated with horseradish
peroxidase (HRP) (1:1000 anti-mouse IgG (Vector Labs), 1:1000
anti-rabbit IgG (Vector labs)) were incubated and exposed to X-
film (Genesee).
Immunofluorescence assay
TIVE-L1 cells were cultured overnight on glass coverslips in 6-
well plates. After fixation with 3% paraformaldehyde for 20 min
and permeabilization with 0.2% Triton X-100 for 15 min, cells
were incubated in blocking buffer (TBS+10% horse serum)
following by rabbit anti-LANA YT041 (diluted 1:500) or mouse
anti-Hsp90 (diluted 1:500). Slides were then incubated with
appropriate secondary antibody anti-rabbit Texas red conjugated
or anti-mouse FITC-conjugated (Vector laboratory) and counter-
stained with DAPI. Images were obtained using a Leica model
DM4000B microscope, with 100-fold magnification; software,
SimplePCI version 6.2).
Immunohistochemistry
Solid tumors were fixed in 10% neutral buffered formalin for 2
days, and paraffin-embedded. Following procedures previously
described [51], slides were first deparaffinized using Histochoice
Clearing Agent (Sigma) and then rehydrated. Endogenous
peroxidase activity was quenched with 3% H2O2 in 10%
methanol, then sections were blocked in solution B (10% horse
serum [Vector laboratory], 5% BSA and 0.3% Triton X-100 in
PBS) for 1 hour at RT, followed by incubation overnight at 4uC
with primary antibodies: phospho-Akt (S473, 1:100), LANA (ABI,
Figure 1. Purification and identification of LANA binding proteins. (A) Outline of biochemical purification baits all of which pulled down
Hsp90; (1.) wild-type, unmodified LANA; (2.) as used to derive partners listed in table 1; (3.) as used to derive partners listed in table 2. The
abbreviations denote epitopes: F for DYKDDDDK, HA for YPYDVPDYA and EQEQE which is repeated within the LANA central domain. (B) Schematic
procedure for purification of LANA complexes using bait 2. Samples were eluted from columns of Sepharose 6B and Heparin FF for purification
separately, followed by immunoaffinity purification with mouse anti-Flag M2 affinity gel and immunoprecipitated using anti-LANA mab. (C) SDS-
PAGE analysis was performed by 8–16% gradient gel and stained with colloidal blue. (D) Schematic procedure for purification of LANA mutant
complexes using bait 3. (E) SDS-PAGE analysis was performed by 8–16% gradient gel and stained with colloidal blue. Co-IP, immunoprecipitation; M,
molecular mass (in kDa).
doi:10.1371/journal.ppat.1003048.g001
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1:200), and ephrin B2 (1:100); solution B was used as negative
control. After washing in PBS, sections were incubated with
appropriate biotinylated secondary antibodies followed by Avidin
DH (Vectastain ABC kit, Vector laboratory) administration, after
which sections were stained with Vector NovaRed substrate
(Vector laboratory). Slides were counterstained with hematoxylin
(Sigma), dehydrated using graded alcohols, cleared in xylene and
mounted in Permount (Sigma). Images were observed using Leica
DM LA histology microscope equipped with a 106/0.25
numerical aperture or a 406/0.75 numerical aperture N plan
objective and a Leica DPC 480 camera.
Knockout of Hsp90 with shRNA lentivirus
Two pLKO.1 lentiviral vectors (TRCN000008749, Target
sequence: 59-CGCATGATCAAGCTAGGTCTA and TRCN
000008750, Target sequence: 59-CCAACTCATGTCCCTCAT-
CAT) targeted for Hsp90 (NM_007355) were obtained from Open
Biosystems/Thermo Inc. The reconstructed lentiviruses were
produced by the Lenti-shRNA Core Facility of University of
North Carolina. BC-1 and BCBl-1 cells (56105) were grown in six-
well plates, infected with lentiviruses separately by adding
polybrene at a final concentration of 10 mg/ml and incubated at
37uC for 6 hrs. After infection, BC-1 and BCBL-1 cell medium
was replaced with fresh RPMI 1640 supplemented with 10% fetal
bovine serum. On the second day, puromycin (5 mg/ml) was
added to the medium. Finally, all the cells were harvested after
infection for four days. Empty lentivirus (shRNA) or untreated BC-
3 cells were used as controls.
IC50 assay
The real-time growth of adherent cells was monitored by
xCELLigence system (Roche Diagnostics, Indiana, IN). 2500 cells
of L1T2, KS-IMM, SLK and SLK-KSHV were seeded on
specialized microplates that contain microelectronic sensor arrays
at the bottom of the wells. Different concentrations of Hsp90
inhibitors (17-DMAG, PU-H71, NVP-AUY922, BIIB021 and
NVP-BEP800) or vehicle were added to the plate after 20 hours of
cellular growth. Two-fold serial dilutions of 17-DMAG, PU-H71,
BIIB021, NVP-BEP800 (0, 10, 20, 40, 80, 160, 320 and 640 nM)
or NVP-AUY922 (0, 2, 4, 8, 16, 32 and 64 nM) were used for
analyses. IC50 was determined at the time of 72 or 96 hours
dependent on cell type after growing for up to 120 hours. Each
experiment was repeated twice. Live cells that adhere to the
bottom of the well result in higher impedance (Cell Index), and
dying cells lose contact thereby lowering the Cell Index. Effect of
drug treatment on KS cells was determined by monitoring the
electronic impedance every 30 min over a period of 120 hours.
Growth curves and IC50 plots were generated using RTCA
Software v1.2 (ACEA Bio. Inc.).
Colony formation assay
400 L1T2 cells were seeded after counting in 10 cm dish with
growth media (as above) supplemented either with vehicle or drugs
at serially diluted concentrations (0, 10, 20, 40 and 80 nM for 17-
DMAG, PU-H71 and BIB021; 0, 20, 40, 80 and 160 nM for
NVP-BEP800; 0, 1, 2, 4 and 8 nM for AUY922). Growth of
colony formation was monitored over a period of 2-weeks. At the
end of the assay, colonies were stained with Magic Blue Stain (3 g
crystal violet and 0.92 g of Ammonium oxalate in 20% ethanol)
and assessed visually by counting the number of colonies formed.
Each experiment was repeated three times.
Real-time quantitative PCR
0.5 mM 17-DMAG was added into PEL cells (BC-3, BCP-1,
BCBL-1 and BC-1), and cells were harvested after 0, 12 and
24 hours. Total RNA was isolated by TRI REAGENT (Sigma;
Saint Louis, MO) and purified by Oligotex mRNA purification
system (Qiagen, CA) according to supplier’s protocol. Reverse
transcription was performed with 0.5 mg random hexanucleotide
primers (Amersham Pharmacia Biotech). Real-time qPCR was
used to detect the viral genome as previously described [52]. The
values were relative to the housekeeping gene GAPDH. Primers
were used as listed: LANA forward (59-39): CGAGAGGAAG-
TTGTAGGAAACG, LANA reverse (59-39): CTTCCAGGTA-
TAGGCAAGGTG; Rta forward (59-39): TGTAATGTCAGC-
GTCCACTC, Rta reverse (59-39): ATTGCTGGGCCACTA-
Table 1. Result of MS/MS for Flag-LANA associated proteins
(,1,000 aa).
ID Name Size MW (Da) MS Score comment
CAA46472 HNR hnRNP
U protein
806 88890.2 15 106 TR
NP_031381 HSP 90-beta 724 83212.1 31 714 HSP
NP_031381 HSP 90-beta 724 83212.1 19 190 HSP
AAQ88940 disulfide isomerase 747 86071.9 19 332 .
AAH68458 Ezrin 586 69198.6 28 252 .
AAA52614 HSPA5/GRP78
precursor
653 72071.2 16 294 HSP
AAH30634 heat shock HSPA9
protein
681 73808 29 1110 HSP
NP_006588 heat shock cognate
71 kDa
724 70854.2 26 919 HSP
BAG70196 ATP-dependent RNA
hel.
614 69077.7 29 872 .
AAS94255 PIG48/chaperonin 545 60540.3 18 188 HSP
NP_004528 nucleosome assembl. 391 45345.9 10 219 .
EAX09924 chaperonin
containing TCP1,
547 59440.4 16 274 HSP
CAG33456 HSPC117 505 55227.9 17 329 .
CAI41893 tubulin, beta 426 47736 22 944 .
CAG33059 HNRPH1 449 49099.3 16 482 TR
NP_817126 actin like protein 6A 387 43208.4 11 223 .
BAD97046 IL enhancer binding
factor 2
390 43021.2 15 379 .
AAH08633 actin, beta 368 40978.4 20 945 .
NP_919223 HNR A3 378 39570.6 12 224 TR
NP_112533 HNRA2/B1 i
soform B1
353 37406.7 30 929 TR
NP_067676 HNR H3 isoform b 331 35216.4 19 391 TR
NP_002128 HNR A2/B1
isoform A2
341 35983.9 31 1260 TR
NP_002127 HNR A1 isoform a 320 34175.2 17 664 TR
CAA27638 Protein G 480 51837.5 7 299 .
NP_057123 homeobox prox 1 244 28050.7 18 294 .
AAC37629 IgG 113 12356.2 7 204 .
HSP: heat shock protein family.
TR: previously identified as KSHV TR binding [91,92].
doi:10.1371/journal.ppat.1003048.t001
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TAACC; GAPDH forward (59-39): ACATCGCTCAGACAC-
CATG, GAPDH reverse (59-39): TGTAGTTGAGGTCAAT-
GAAGGG.
Flow cytometry assay
For cell cycle analysis, cells fixed in 70% ethanol were
resuspended in phosphate-buffered saline with 20 mg/ml propi-
dium iodide, 200 mg/ml RNase A and 0.1% Triton X-100. For
apoptosis analysis, cells were stained with FITC conjugated anti-
Annexin V antibody. Flow cytometry analysis was performed by
using CyAn (Beckman-Coulter, Fullerton, CA). Further analysis
was conducted with FlowJo (version 7.6.5; Tree Star, Inc.,
Ashland, OR) and R version 2.15.1 (2012-06-22).
Animal studies
16105 L1T2 cells were counted after washing with PBS once,
diluted into 100 ml PBS and mixed with 100 ml growth factor-
depleted Matrigel (BD Biosciences, Bedford, MA). 16105 cells
were injected sub-cutaneous into the flank of C.B.-17 SCID mice
(Jackson Laboratory, Bar Harbor, MN) following our previously
validated procedures [53]. Two groups were used for experiment
and control; each group had 6 mice. The mice were observed
every one or two days for the presence of palpable tumors. Three
days post-injection, a single dose of 50 mg/kg AUY922 or vehicle
was injected intra-peritoneal as previously described [54]. Tumor
diameters were determined by caliper measurements. Tumor
volume was calculated as V = a * b * c, where a, b, and c are the
three diameters (length, breadth and width) of the tumor. The
tumors were excised from the site of injection and fixed in formalin
(Fisher Diagnostics, Middletown, VA).
Results
Hsp90 interacts with KSHV LANA
LANA is essential for maintaining latent KSHV, which is a
prerequisite for PEL and KS tumorigenesis. Thus, it is of
continued interest to identify cellular binding partners of LANA.
We previously purified authentic LANA complexes from the BC-3
PEL cell line [40]. In the context of PEL (and KS) most of the
LANA is tethered to the viral episome. To identify LANA binding
partners that are important in protein maturation and in functions
of LANA that are not tightly linked to DNA binding we stably
expressed full length FLAG-tagged LANA or a mutant in KSHV-
negative BJAB cells (Figure 1A). Then we used two-step
chromatographic isolation (Sepharose 6B and Heparin FF
column), followed by sequential immunoaffinity purification
(Tag-TAP) with two different monoclonal antibodies; mouse
anti-FLAG against the N-terminal epitope tag and rat anti-LANA
(against the EQEQE repeat epitope) against the central repeat
region (outlined in Figure 1B). We previously found that heparin
FF bound intact LANA complexes [48] consistent with its
established use as initial step in many of the early transcription
factor isolation studies. LANA binding proteins were resolved by
8–16% gradient SDS-PAGE (Figure 1C) and subjected to MS/
MS. We identified heat shock protein Hsp90-beta (NP_0310381).
We also found several other heat shock proteins such as HSPA9
protein (AAH30634), and heat shock cognate 71 kDa protein
isoform1 (NP_006588) (Table 1). This corroborates our prior
work, where we co-purified HSPs as one of many binding partners
of authentic full length LANA in PEL [40]. To confirm our
experiments and because of potential non-specific interactions
with the central repeat region we generated a stable BJAB cell line
expressing a mutant LANA protein, which had a deletion of the
central repeat region, and which was engineered to have both a
FLAG and HA tag at the N-terminus (Figure 1A). Again we
performed Tag-TAP purification on nuclear extracts (Figure 1D),
resolved individually associated proteins on SDS-PAGE
(Figure 1E) and identified visible bands by MS/MS. The result
confirmed the association with Hsp family members (Table 2).
These three independent biochemical purifications using different
antibodies and different ‘‘bait’’ constructs demonstrate that LANA
is associated with cellular heat shock proteins, and that this
interaction occurs independently of other viral proteins or viral
DNA.
To investigate the interaction between LANA and Hsp90, we
used WT FLAG-tagged LANA and FLAG-tagged mutant
derivatives, the N-terminal or C-terminal of LANA (or both).
After co-transfection of full-length FLAG tagged LANA (or LANA
mutants) and HA-tagged-Hsp90 in HeLa cells, immunoprecipita-
tion was performed with anti-FLAG antibody to bait Hsp90
complexes; the complexes separated by SDS-PAGE and associated
protein detected with anti-HA antibody. We found that full-length
LANA bound to Hsp90, and that the N-terminal of LANA but not
the C-terminal interacts with Hsp90 (Figure 2A). The reverse
immunoprecipitation assay demonstrated that Hsp90 binds to full-
length LANA (Figure 2B). This experiment verified that N-
terminal LANA associates with Hsp90.
Because the location of LANA is strictly limited to the nucleus,
while Hsp90 is distributed in the cytoplasm but in virus infected
cells has also been observed in the nucleus [55], we investigated
whether both proteins co-localize. We used the KSHV positive
endothelial tumor cell TIVE-L1 [23]. Cells were incubated with
rabbit anti-LANA and mouse anti-Hsp90 antibodies and visual-
ized using appropriate secondary antibodies (conjugated with
Texas Red or FITC) (Figure 2C). LANA was located within
Table 2. Result of MS/MS for HA-Flag-LANA-dCR (pMF-24)
associated proteins (,1,000 aa).
ID Name Size MW(Da) MS Score comment
EAW84989 drebrin 1, isoform
CRA_a
687 75526.4 22 410 .
CAA46472 hnRNP U protein 806 88890.2 11 152 TR
Q53GZ6 HSP 70 kDa protein
8 iso 1variant
646 70855.2 23 591 HSP
AAB62657 LANA (orf73) 1089 126157.6 13 287 .
AAH30634 heat shock
HSPA9 protein
681 73808 26 651 HSP
NP_006588 heat shock
cognate 71 kDa
646 70854.2 21 202 HSP
NP_033784 serum albumin
precursor
608 68647.7 12 419 .
AAH08237 IgH protein 463 51326.5 10 288 .
AAH08237 IgH protein 463 51326.5 5 682 .
AAH12854 ACTB 360 40194.1 15 179 .
AAH08633 actin, beta 368 40978.4 26 1560 .
AAH08237 IgH protein 463 51326.5 10 160 .
CAA27638 Protein G 480 51837.5 5 304 .
AAH07308 RPS4X protein 263 27242.7 7 66 RIBO
2J4W_L Chain L 213 23246.1 11 633 .
HSP: heat shock protein family.
TR: previously identified as KSHV LANA-TR binding [91,92].
RIBO: previously identified as LANA binding in PEL [40].
doi:10.1371/journal.ppat.1003048.t002
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nuclei of TIVE-L1 cells (Red) in the characteristic punctuate
pattern. Part of Hsp90 was distributed within nuclei as previously
described [56], and much of it in the cytoplasm (Green). A fraction
of LANA and Hsp90 co-localized in the nucleus (Yellow). It is not
clear at this point whether these co-localizing complexes represent
functional episome tethering complexes or dead-end miss-folded
accumulations.
Hsp90 specific inhibitors disrupt the interaction between
LANA and Hsp90
To query the functional significance of the LANA-Hsp90
interaction, we used chemical inhibitors of Hsp90. The Hsp90
inhibitor, 17-dimethylamino-ethylamino-17-demethoxygeldana-
mycin (17-DMAG), disrupts Hsp90-client complexes, and reduces
client protein levels, e.g. REV1, BCL6, or FANCA, through
subsequent proteasomal degradation [56,57,58]. We hypothesized
that 17-DMAG could similarly disrupt the interaction between
LANA and Hsp90. To test this hypothesis, we treated BCBL-1
cells with 0.5 mM 17-DMAG at 0, 3, 6, 12, 24 hours, then
immunoprecipitated LANA using a rat monoclonal antibody
followed by immunoblotting analysis with anti-Hsp90 antibody.
LANA disassociated from Hsp90 after incubation with 17-DMAG
within 6 hours (Figure 3A). At 24 hours, we observed for the first
time a reduction in LANA input levels, preferentially in the lower
bands. This is expected because of the long half-life of LANA.
More pronounced effects on overall LANA levels are only seen
after 48 hours (Figure 4). The timing of cytotoxic inhibitor
experiments is somewhat difficult as we are trying to measure a
biochemical effect at the highest inhibition of Hsp90, but at a time
where cells are not already dead.
To confirm the 17-DMAG results we used the new highly
specific, ATP-competitive inhibitor of Hsp90 AUY922
[54,59,60,61,62,63]. BCBL-1 cells were treated with AUY922
for 24 hours at increasing concentrations, followed by immune
precipitation using anti-Hsp90 antibody and immunoblotting with
anti-LANA antibody. AUY922 disrupted the LANA-Hsp90
complexes in BCBL-1 cells at 10–100 nM (Figure 3B). We and
others had previously shown that LANA bound p53 [46,48,64]. As
expected the LANA:p53 complexes were also diminished in the
same concentration range.
To show independence of these interactions from other viral
proteins and viral DNA we performed transient transfections.
HeLa cells were transfected with a LANA expression vector for
24 hours after which AUY922 was added for 5 hours post-
transfection. Again the Hsp90 inhibitor disassociated Hsp90 from
LANA complexes (Figure 3C). In these experiments non-specific
IgG was used as control. This demonstrates that functional
inhibition of Hsp90 results in the disruption of the Hsp90-LANA
complex.
Hsp90 inhibitors induce proteasomal degradation of
LANA
17-DMAG is known to accelerate degradation of Hsp90 client
proteins [57,58]. To test the hypothesis that 17-DMAG had a
similar effect on the stability of LANA we monitored LANA
protein levels after blocking de novo protein synthesis with
cycloheximide (CHX). Since Hsp90 binds to the N-terminal of
Figure 2. Analysis of interaction between LANA and Hsp90. (A) Interaction between Hsp90 and LANA or respective LANA mutants in HeLa
cells. HA-tagged Hsp90 was co-transfected with Flag-tagged full-length LANA (aa1–1162) or indicated mutants: Flag-tagged LANA-N (aa1–329,
pDD1928), Flag-tagged LANA-C(aa930–1162,pDD1931), or Flag-tagged LANA N+C (aa1–329 and 928–1162, pDD775). Protein extracts were
immunoprecipitated with anti-Flag antibody followed by immunoblotting with anti-HA antibodies, IgG was used as control. Input samples were from
cell lysate supernatants. MW markers in kD are indicated on the left. (B) Reverse immunoprecipitation. HA-tagged Hsp90 together with Flag-tagged
LANA were co-transfected into HeLa cells, empty pcDNA vector was used for control. Protein extracts were immunoprecipitated with anti-HA
antibody and immunoblotted with anti-LANA antibody. Input samples were from cell lysate supernatant. (C) Co-localization analysis of LANA and
Hsp90. Immunofluorescence assay was performed after fixation and permeabilization of TIVE-L1 cells, incubated with primary rabbit anti-LANA and
mouse anti-Hsp90 antibodies and the secondary anti-rabbit Texas (red) and anti-mouse FITC (green) conjugated antibodies respectively. Nuclear
fractions were stained with DAPI, images were observed under fluorescence microscope.
doi:10.1371/journal.ppat.1003048.g002
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LANA but not the C-terminal (Figure 2A), we first determined
the half-life of N- and C- terminal LANA proteins. Using transient
transfection in Hela cells, we determined that the N-terminal
domain of LANA was significantly more stable than the C-
terminal domain of LANA, (Figure 4A), consistent with our
conjecture that Hsp90 binding to the N-terminal domain
contributed to overall stability. Next, we compared the half-life
of transiently transfected full-length LANA after treatment with
17-DMAG to treatment with vehicle. 17-DMAG reduced the
half-life of LANA by several hours compared to vehicle control
(Figure 4B) while not affecting actin levels. These data were
quantitated as shown in Figure 4, panel C and D. This establishes
LANA as a client protein of Hsp90.
How was LANA degraded after Hsp90 inhibition? LANA
protein accumulated after treatment with the proteasomal
inhibitors Lactacystin and MG-132 in the presence of 17-DMAG
(Figure 4E–F). As a control we used cdc2, which is an established
client protein of Hsp90 [65]. MG-132 also increased in
endogenous LANA levels in the BCBL-1 PEL cell line after
treatment with AUY922 (Figure 4G). LANA levels were not
affected by the autophagy inhibitor 3-Methyladenine (data not
shown). These experiments are difficult, as they require titration of
two drugs against two proteins, cdc2 and LANA, with different
half-lives and differing dependencies on Hsp90. Nevertheless they
suggest that LANA like other Hsp90 client proteins is degraded by
the proteasome pathway.
To independently confirm these experiment we investigated
LANA poly-ubiquitinylation in response to 17-DMAG, which
represents one hallmark of entry into the proteasomal degradation
pathway. Cell lysates of full length LANA plasmid-transfected
HeLa cells treated with 17-DMAG or vehicle control in the
presence MG-132 were used for immunoprecipitation with anti-
LANA antibody. Immunoprecipitates were subjected to SDS-
PAGE followed by immunoblotting with anti-LANA or anti-
ubiquitin antibody. Of note LANA itself is a very large protein and
runs at the top of even low-percentage SDS-PAGE gels. Some
ubiquitinated LANA was present in cells after treatment with
MG132 alone, but Hsp90 inhibition dramatically increased the
poly-ubiquitination of LANA, as detected by a smear in the
presence of 17-DMAG (Figure 4H). This demonstrates that
Hsp90 targets miss-folded LANA for degradation through the
ubiquitin-based proteasome pathway.
Inhibition of Hsp90 changed the characteristic nuclear punc-
tuate pattern of LANA. When we added 17-DMAG in L1T2 cells
for 48 hours at a concentration of 0.5 mM, LANA specific staining
changed from a punctuate pattern into smaller dots irregularly
distributed throughout the nucleus (Figure 4I). This result
confirms our biochemical experiments and suggests the possibility
that Hsp90 activity is required to maintain multimeric LANA
complexes.
To determine whether Hsp90 inhibitors affect LANA tran-
scription, we examined mRNA levels of LANA. BC-3, BCBL-1,
BCP-1 and BC-1 cells were treated with 0.5 mM 17-DMAG for 0,
12 and 24 hours, and mRNA levels were measured by real-time
qPCR. Relative expression was computed by comparison to the
housekeeping gene GAPDH. The mRNA levels of LANA were
unchanged upon Hsp90 inhibition (data not shown). We also
examined the mRNA levels of RTA, an essential immediate early
gene of KSHV. RTA levels also were unchanged. This
demonstrated that LANA and Rta were not influenced by
Figure 3. Hsp90 inhibitors disassociate LANA and Hsp90. (A) BCBL-1 cells were harvested after treatment with 0.5 mM 17-DMAG for 0, 3, 6, 12,
24 hours separately, cells lysates were immunoprecipitated with rat monoclonal anti-LANA antibody, followed by immunoblotting analysis with
mouse anti-Hsp90 and anti-LANA antibodies. Input samples were from supernatants of lysed cells. (B) BCBL-1 cells were harvested after treatment
with 0, 10, 100 and 1000 mM AUY922 separately for 24 hours, cell lyses were used for immunoprecipitation assay with anti-Hsp90 and anti-p53
antibodies, followed by immunoblotting analysis with anti-LANA. (C) Hela cells were transfected with LANA vector treated with no drug (DMSO) or
0.1 mM AUY922 for 24 hours. Immunoprecipitation was performed with rat anti-LANA antibody, followed by immunoblotting analysis with anti-LANA
and anti-Hsp90 antibodies; IgG was used as control.
doi:10.1371/journal.ppat.1003048.g003
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Figure 4. Hsp90 inhibitors induce proteasomal degradation of LANA. (A) Half-life analysis of LANA termini. N- or C- termini of Flag-tagged
LANA vectors were transfected separately into HeLa cells for 16 hours, followed by cycloheximide (CHX) treatment for 0, 3, 6, 12, 24 and 48 hours.
Whole cells lysates were immunoblotted with anti-Flag antibody. b-Actin was used for loading control. (B) LANA degradation induced by 17-DMAG.
HeLa cells were transfected with full-length LANA overnight, followed by incubation with vehicle or 0.5 mM 17-DMAG in the presence of 50 mg/ml
cycloheximide for 0, 3, 6, 12, 24 and 48 hours respectively, whole cells lysates were immunoblotted with anti-LANA. (C–D) Quantitative analysis of the
above results. (E–F) LANA degradation inhibited by MG-132 or Lactacystin. After transfection with LANA vector, Hela cells were treated with no drug
or 17-DMAG (1 mM) for 24-hours in the absence (2) or presence (+) of proteasome inhibitor MG-132 (10 mM) for the last 6 hours or Lactacystin
(10 mM) for 24 hours, whole cells lyses were immunoblotted with anti-LANA antibody. (G) Proteasomal degradation of LANA in BCBL-1 cells. BCBL-1
HSP90 in Kaposi Sarcoma
PLOS Pathogens | www.plospathogens.org 8 November 2012 | Volume 8 | Issue 11 | e1003048
inhibition of Hsp90 at the transcriptional level, which implies that
the reduction in LANA protein levels is not caused by
transcriptional repression after drug treatment.
The repeat sequence of the LANA central domain is
dispensable for Hsp90 action
Epstein-Barr Virus (EBV) encodes a functional, but not
sequence homolog to LANA, the EBV nuclear antigen 1 (EBNA1).
Both proteins have many characteristics in common: both are
responsible for tethering the viral episome to host DNA in infected
cells, and both proteins have unique central repeat domain that
links the N-terminal to the C-terminal DNA binding domain.
EBNA1 contains a Gly-Ala repeat, which mediates the Hsp90
enhancement of EBNA1 expression [66]. LANA has an acidic
QED-rich repeat central repeat (CR) region that serves as the
connector. Therefore we compared the effect of Hsp90 inhibition
on LANA to EBNA1 in transiently transfected HeLa cells. LANA
protein levels decreased gradually in a dose-dependent mode after
treatment with 17-DMAG for 48 hours. Here, cdc2 was chosen as
a cellular control, as it is a known substrate of Hsp90 [65]
(Figure 5A). EBNA1 protein levels were also rapidly reduced even
at very low concentrations of 17-DMAG (Figure 5B). Impor-
tantly, protein levels of a LANA mutant in which the acidic central
repeat was deleted (LANA Mu (N+C)) were also diminished after
treatment with 17-DMAG (Figure 5C). We used actin as a
loading control and, cdc2 as control for Hsp90 inhibition. This
demonstrates that the central region of LANA does not mediate
Hsp90 interaction. It is consistent with our mapping data, which
showed that Hsp90 bound the N-terminal domain of LANA. It
suggests that the molecular mechanism of Hsp90-mediated
stabilization of LANA differs from that of Hsp90-mediated
stabilization of EBNA1.
Hsp90 inhibitors have therapeutic potential against PEL
Having demonstrated that Hsp90 was an important molecular
chaperone of LANA, we explored the potential of Hsp90
inhibitors as anti-PEL tumor therapeutics. We used cleaved
caspase-3 as a marker for cell death. We treated PEL cells with the
Hsp90 inhibitor 17-DMAG at different concentrations (0, 0.1, 0.5
and 2.5 mM) for 48 hours. BC-3 and BCBL-1 cells were more
sensitive to 17-DMAG compared to BCP-1 and BC-1. The
appearance of cleaved caspase-3 as a marker of apotosis was at
lower concentrations 500 nM and 100 nM in BC-3 and BCBL-1,
respectively (Figure 6 A and C). LANA expression, too, was
readily diminished at sub-micromolar concentrations of the
inhibitor. Apoptosis in PEL involves p53 and this phenotype
correlated with p53 status [67]. BC3 and BCBL-1 have wild-type
functional p53 and were more sensitive to 17-DMAG, BCP-1 and
BC-1 have mutant p53 and were less sensitive to 17-DMAG. Of
course, p53 status is not the only difference among these [68].
They required 2.5 mM 17-DMAG to induce caspase-3 cleavage.
As an additional cellular Hsp90 control we investigated Akt,
which is a known client protein of Hsp90. Akt and Akt/mTOR
signaling is required for PEL growth [51,69]. Akt was decreased in
all PEL cells in a dose-dependent manner after 17-DMAG
treatments as was cdc-2. Again, in BC-3 and BCBL-1 cdc-2
expression was abrogated at 100 nM inhibitor, whereas 500–
2500 nM were needed to show a similar downregulation of cdc-2
in BCP-1 and BC-1 cells (Figure 6 A–D). In sum, multiple Hsp90
client proteins are degraded upon exposure of PEL to 17-DMAG,
many of which (LANA, K1 [50], Akt) with known oncogenic roles
in PEL tumorigenesis.
To extend our observations with regard to the therapeutic
potential of Hsp90 inhibitors for PEL, we treated multiple PEL cell
lines with three different Hsp90 inhibitors at different concentra-
tions for 24 hours as indicated and measured apoptosis by flow
cytometry for annexin V (Figure 6E–G). We used 17-DMAG,
AUY922 and a third, novel ATP-competitive Hsp90 inhibitor PU-
H71 [70]. All induced apoptosis in a dose-dependent fashion
(p#5*10216, by ANOVA). The p53 wild type BC-3 was the most
sensitive and the p53 mutant BCP-1 the least sensitive cell line
independent of drug and concentration (p#0.015 for BCP-1,
p#0.003 for BC3, based on ANOVA. The difference between
BCP-1 and BC3 was p#0.000001 based on Tukey-HSD test). BC-
3 cells showed 38.7% apoptosis while BCP-1 cells showed only
18% apoptosis when treated with 10 mM 17-DMAG. All PEL lines
seemed more sensitive to AUY922 than to the other two drugs,
though this did not reach a level of statistical significance at a 95%
family-wise confidence level (Figure 6F). As with all chemical
inhibitor studies we cannot exclude that differential sensitivity is a
function of different drug entry and efflux from cell. In sum,
were treated for 24 hours with no drug or AUY922 (0.1 mM) in the absence (2) or presence (+) of proteasome inhibitor MG-132 (10 mM) for the last
6 hours, whole cells lysates were immunoblotted with anti-LANA antibody. (H) Poly-ubiquitinated degradation of LANA. HeLa cells were transfected
with LANA, followed by treatment with no drug or 1 mM 17-DMAG for 24 hours in the presence of DMSO or 10 mM MG-132 for the last 6 hours. Cells
lysates were immunoprecitated with rat anti-LANA antibody, followed by immunoblotting with rabbit anti-ubiquitin and anti-LANA antibodies, the
bracket shows the poly-ubiquitinated LANA (Ub-LANA). (I) Immunofluorescence analysis of LANA degradation. L1T2 cells were treated with no drug
or 1 mM 17-DMAG for 48 hours, incubated with primary anti-LANA (rabbit) and after fixation and permeabilization, stained with anti-rabbit Texas-Red
conjugated antibodies (red, LANA), nuclei were stained with DAPI.
doi:10.1371/journal.ppat.1003048.g004
Figure 5. Central repeat domain of LANA resists degradation.
(A–C) HeLa cells were transfected with plasmids including full-length
LANA, LANA mutant (deleted repeat central domain) and EBNA1
respectively in six-well plates, followed by treatment with 17-DMAG at
concentrations of 0, 0.1, 0.5, 2.5 and 10 mM for 48 hours. Whole cells
lysates of each sample were immunoblotted with anti-LANA and anti-
Flag antibodies, Cdc2 and b-Actin were used as controls.
doi:10.1371/journal.ppat.1003048.g005
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Figure 6. Effects of Hsp90 inhibitors on LANA in PEL cells. (A–D) Hsp90 inhibitors repress LANA expression in PEL cells. PEL cells including BC-
3, BCP-1, BCBL-1, and BC-1 cells were treated with 17-DMAG at concentrations of 0, 0.1, 0.5, 2.5 and 10 mM and after 48 hours, whole cells lysates
were immunoblotted with anti-LANA, anti-Hsp90, anti-Akt, and anti-cleaved caspase-3 antibodies, Cdc2 and b-Actin were used as controls. (E–G)
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established and novel Hsp90 inhibitors inhibit cell growth and
apoptosis in PEL cells.
Sh-RNA mediated knockout of Hsp90 leads to PEL
apoptosis
To guard against the possibility of off target effects of chemical
Hsp90 inhibitors, we used recombinant lentiviruses. Two vectors,
Sh-A and Sh-B, which target Hsp90 were transduced into BCBL-1;
empty lentivirus or untreated cells were used as controls. Hsp90
protein levels were dramatically reduced compared to untreated
cells upon specific shRNA transduction with either sh-A or sh-B, but
not irrelevant control (Figure 7). Upon depletion of Hsp90, the
protein levels of LANA and the host control client protein Akt were
decreased compared to controls. Lentivirus Sh-A was slightly more
efficient than Sh-B and was also used in BC-1 cells with the same
result: upon reduction of Hsp90, the level of LANA decreased as
well. At the same time, expression levels of both cleaved PARP and
Caspase-3 were increased indicative of apoptosis. This demonstrates
that Hsp90 is essential for the survival of PEL and that direct
inhibition of Hsp90 rather than off target effect of the drugs mediate
the therapeutic efficacy of Hsp90 inhibitors against PEL.
Hsp90 inhibitors inhibit KS tumor growth and reduce
ephrin-B2 and EphA2 levels
In addition to PEL, which is a B cell lymphoma, KSHV is also
associated with the development of KS, an endothelial lineage
tumor. To explore the potential of Hsp90 inhibitors as novel anti-
KS therapeutics we used KS culture and animal models. The
L1T2 cell line was established from KSHV positive L1-TIVE cells
[23]. It is more aggressive than the parent line and readily induces
tumors in SCID mice (Roy and Dittmer, submitted). L1T2 cells
were treated with increasing doses of AUY922 for 48 hours
(Figure 8A). Immunoblotting confirmed that LANA protein levels
were decreased in a dose-dependent manner. Cdc2 protein levels
were used as control for Hsp90 inhibition and also decreased in a
dose-dependent manner. Actin protein levels were used as control
for loading and remained constant independent of the dose of
AUY922. At the same concentration that cdc2 levels decreased,
Akt, and phosphorylated Akt protein levels were decreased. This
confirmed the specificity of the inhibitor for Hsp90. Cleaved
Caspase-3 was increased. Similar results were observed in another
KS cell model after treatment with a different Hsp90 inhibitor.
SLK-KSHV [47] were treated with 17-DMAG with different
dosages (0, 0.1, 0.5, 2.5 and 10 mM) and times (0, 12, 24, 48, 72
and 96 h) and LANA protein levels were reduced in a dose- and
time-dependent manner (Figure 8 B–C). Note that in this model
cell growth is not dependent on LANA, which supports the notion
of LANA as a direct target of Hsp90.
KS tumorigenesis is more complicated than PEL tumorigenesis
in that KSHV re-infection seems to contribute to the transformed
phenotype [47]. Recently, the EphA2 receptor tyrosine kinase was
implicated as a co-receptor for KSHV [34,35]. Hsp90 is an
essential regulator of EphA2 stability [71]. Therefore, we tested
the hypothesis that EphA2 is also a client protein of Hsp90 in KS.
EphA2 expression was reduced in the two KS cell lines (L1T2,
SLK-KSHV) after treatment with two different Hsp90 inhibitors
(Figure 8). The reduction in EphA2 was both dose and time
dependent, confirming that in KS, as in other cancers, EphA2 is a
client of Hsp90.
KS also expresses ephrin-B2, but not its receptor EphB4.
Ephrin-B2 is critical for the survival of KS tumor cells, while
EphB4 is downregulated upon KSHV infection [19,20,72].
Therefore, we tested the hypothesis that ephrin-B2 is also affected
by Hsp90 inhibition in KS. EphrinB2 protein levels were
decreased in the different KS cell lines after treatment with
Hsp90 inhibitors, in a dose- and time-dependent fashion
(Figure 8). This is the first study implicating ephrin-B2 as a
potential client of Hsp90. Similar to PEL before, we also found
that total Akt protein levels and phosphorylated Akt (S473) were
decreased in L1T2 cells upon exposure to AUY922. This
correlated with a time dependent increase in the levels of cleaved
PARP and caspase-3, which are markers of apoptosis (Figure 9A).
This demonstrates that Hsp90 inhibition decreases essential viral
(LANA) and host (EphA2, ephrin-B2, Akt) client protein levels in
KS resulting in cell death.
Hsp90 inhibitors repress proliferation of KS
To expand our observations we measured the effect of Hsp90
inhibitors on KS cell growth. First, we used the xCELLigence
system to measure proliferation in real-time, and we added two
additional Hsp90 inhibitors, BIIB021 and NVP-BEP800. SLK-
KSHV, L1T2, SLK and KS-IMM were treated separately with
17-DMAG, PU-H71, AUY922, BIIB021 and NVP-BEP800. IC50
values were determined based on real-time growth curves using
the XCelligence system (Table 3). All Hsp90 inhibitors had
nanomolar IC50s. AUY922 was the most efficacious among these
five drugs. It had single nanomolar or even sub-nanomolar IC50
against all cell lines, which was an order of magnitude lower than
Apoptosis. PEL cells including BC-3, BCP-1, BCBL-1, and BC-1 cells were treated respectively with Hsp90 inhibitors 17-DMAG and PU-H71 at
concentrations of 0, 1, and 10 mM, and 10 mM, or 0, 0.1 mM AUY922 for 24 hours, apoptosis percentage was analyzed after PEL cells were harvested
and stained.
doi:10.1371/journal.ppat.1003048.g006
Figure 7. Effects of Hsp90 on LANA after lentiviral knockout.
BCBL-1 and BC-1 cells were infected with recombinant lentiviruses
targeting Hsp90 in six-well plates; empty lentivirus vector and
untreated cells were used as controls. Samples were harvested after 4
days and immunoblotted with anti-LANA, anti-Hsp90, and anti-Akt
antibodies, respectively. Apoptosis was evaluated by immunoblotting
assay with anti-cleaved PARP and Caspase-3 antibodies separately. b-
Actin was used as loading control.
doi:10.1371/journal.ppat.1003048.g007
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the IC50 for the other Hsp90 inhibitors. NVP-BEP800 was least
effective, possibly due to a weak solubility [73].
The results also indicated that every Hsp90 inhibitor was more
effective in the KSHV-positive SLK cells compared to isogenic
KSHV-negative SLK cells. This is quantified in table 3, which
shows the range of ratios comparing the IC50 of SLK cells to SLK
cells carrying KSHV. This demonstrates that KS/endothelial
lineage tumors are exquisitely sensitive to Hsp90 inhibition and
that part of this phenotype can be attributed to the presence of
KSHV latent proteins.
To independently verify the potency of the Hsp90 inhibitors, we
performed clonogenic colony formation assays. All drugs inhibited
cell growth with nanomolar IC50s. AUY922 again was the most
efficacious among the five drugs in these assays, with an IC50 of
2 nM (Figure 9A).
Third, we performed cell-cycle analysis. L1T2 cells were treated
with 500 nM of 17-DMAG, PU-H71, BIIB021, NVP-BEP800, or
50 nM AUY922 for 24 hours and subjected to cell cycle profiling
using propidium iodide staining. DMSO treatment was used as a
control. The cells stopped cycling with a reduction in S phase,
which was 20.47% for control and ,9.5% for each of the five drug
treated samples. At the same time the fraction of G0/G1 cells
increased from 58.77% for control to 69.19%–73.67% in each of
the five drug treated cells. AUY922 was as effective as the other
four inhibitors even though it was used at 10 fold lower
concentration (Figure 9B). In sum, Hsp90 inhibitors repress KS
tumor cell proliferation at nanomolar concentrations.
To further investigate the anti-tumor activity of AUY922, we
subcutaneously injected SCID mice with KSHV-infected L1T2
cells (105/mouse) as previously published [53]. Upon the
development of palpable tumors the mice were randomized to
two groups and with AUY922 (50 mg/kg) for three weeks (three
times per week) or vehicle. All the animals were sacrificed after 21
days as per IACUC stipulation. AUY922 significantly retarded
tumor growth compared to the mock-treated mice (p#0.05 by
repeated measurements analysis of variance (ANOVA))
(Figure 9C).
To demonstrate molecular activity of AUY922 in vivo, we
measured Hsp90 client protein levels in the tumor grafts by
immune histochemistry (Figure 10). No staining was observed
without primary antibody. (i) As expected [74,75] phosphorylated
Akt was detectable in all viable tumor cells (excluding those in
liquefied or necrotic areas). The phosphorylation level of Akt was
substantially reduced after AUY922 treatment. (ii) LANA was
detected in the nuclei of KS xenograft mouse tumors, and LANA
levels were reduced after treatment. (iii) ephrin B2 expression was
expressed at substantial levels in all KS cell lines and our
immunohistochemical results detected ephrin B2, in vascular
structures and tumor cells in KS xenograft tumors. Ephrin B2
levels were significantly decreased after AUY922 treatment. These
experiments support the notion that LANA, AKT and ephrinB2
are bona fide targets of Hsp90 in KS tumors in vivo and provide
proof-of-principle for the use of Hsp90 inhibitors as potential anti-
KS therapeutics.
Discussion
This study shows that KSHV LANA is a novel client protein of
Hsp90. Hsp90 associates with the N-terminus of LANA. ATP-
competitive Hsp90 inhibitors disrupt this interaction and reduce
the half-life of LANA by accelerating ubiquitin-mediated,
proteasomal degradation of LANA. LANA plays an essential role
in KSHV genome persistence and KS tumorigenesis [38,76].
Chemical inhibition of Hsp90 or Hsp90 depletion using shRNAs
led to rapid apoptosis of KS tumor cells and inhibited KS
xenograft growth in mice. In addition to LANA, we validated
cdc2, Akt, EphA2 and ephrin-B2 as targets of Hsp90 in KS.
Earlier studies identified additional Hsp90 clients in PEL
[14,15,77]. This establishes Hsp90 as a novel target for anti-viral
and anti-tumor strategies in KS and PEL.
Figure 8. Effects of Hsp90 inhibitors on LANA in KSHV-infected endothelial cells. (A) L1T2 cells were treated with AUY922 at
concentrations of 0, 0.02, 0.1, 0.5, and 2.5 mM for 48 hours, whole cell lysates were immunoblotted with anti-LANA, anti-Hsp90 antibodies, anti-
EphA2, anti-Ephrin-B2, and anti-Akt (total), and anti-pAkt (S473) antibodies separately. Apoptosis was evaluated with anti-cleaved PARP and anti-
cleaved Caspase-3 antibodies, Cdc2 and b-Actin were used as controls. (B–C) SLK-KSHV were treated with 0.5 mM 17-DMAG for 0, 12, 24, 48, 72 and
96 hours, or at concentrations of 0, 0.1, 0.5, 2.5 and 10 mM for 48 hours separately, whole cell lysates were immunoblotted with anti-LANA antibody,
anti-EphA2, anti-EphrinB2, Cdc2 and b-Actin were used as controls.
doi:10.1371/journal.ppat.1003048.g008
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Figure 9. Hsp90 inhibitors repress KS tumor growth. (A) Colony formation assay of L1T2 cells after drug treatment. 400 L1T2 cells were seeded
in 10 cm dishes, followed by addition of two-fold serially-diluted Hsp90 inhibitors; 17-DMAG, PU-H71, AUY922, BIIB021, and NVP-BEP800, respectively
for two weeks. Colonies were counted after incubation with Magic Blue Staining, each experiment was repeated three times. (B) Hsp90 inhibitors
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The dependence on Hsp90 is shared between KSHV LANA
and EBV EBNA1 [66]. Since LANA and EBNA-1 do not share
sequence similarity, yet they are structural and functional
homologs, the mechanism of Hsp90 interactions differs for both
proteins. In case of EBNA1, the central Gly-Ala repeat domain is
required for Hsp90 inhibition [66]; in the case of LANA the N-
terminal domain mediates the Hsp90 interaction, though the
central repeat region may contribute to overall stability as well.
EBNA1 is degraded through autophagy after Hsp90 inhibition;
LANA was degraded through the ubiquitin/proteosome pathway.
There is also the question of cellular localization. Sun et al. [66]
did not find a direct EBNA1:Hsp90 interaction and consequently
did not query where the EBNA1:Hsp90 interaction took place.
They focused their efforts on EBNA1 translation and elegantly
showed that translation of the Gly-Ala repeat required Hsp90 in
an in vitro translation reaction. Our studies show that LANA
affected overall stability of LANA, but also evidence for a nuclear
interaction. Hsp90 can be present in both the cytoplasm and the
nucleus [78,79,80], possibly fulfilling different roles in either
compartment. Most recently nuclear BRCA1 and DNA-PKA
were validated as novel client proteins of Hsp90 [81,82], which
implicates Hsp90 in the DNA damage/repair response. Regard-
less of mechanism, the LANA:Hsp90 interaction can be exploited
to kill KSHV-associated tumors.
Hsp90 inhibitors represent promising drugs for cancer therapy
and many have advanced into phase I clinical trials. We previously
implicated the Hsp90 inhibitor 17-DMAG as a chaperone for the
KSHV K1 protein and showed that it had activity against PEL
cells [50]. 17-DMAG and the related compounds 17-AAG/
Tanespimycin and geldanamycin had varying efficacy in early
clinical trials, due to toxicity, choice of target cancer type, and
perhaps because these compounds are substrates for the P-
glycoprotein efflux pump and have sub-optimal pharmacokinetics
in humans (reviewed in [8]). In addition Hsp90 fulfills crucial
functions in normal cells, in the EBV life cycle [66], and in fact the
lytic replication of other viruses (reviewed in [83,84,85]).
Therefore it has been a concern that very potent Hsp90 inhibitors
would affect basic cell functions non-specifically and that therefore
their selectivity index would be low. For instance, Hsp90 has been
implicated in cardiac potassium channel maturation; yet cardiac
toxicity has not emerged as dose limiting in phase I trials. 17-
DMAG and other benzoquinone derivative cause liver toxicity.
That phenotype was not related to Hsp90 inhibition and
prompted the screen for second-generation Hsp90 inhibitors,
which we explored here. Another potential application is, at least
hypothetically, the treatment of neurodegenerative diseases, which
result in the accumulation of miss-folded proteins. The require-
ment for Hsp90 in cancer cells, virally infected cells or cells that
accumulate misfolded proteins seems to be so profound that it
translates into selectivity in clinical settings for second generation
Hsp90 inhibitors; alternatively it has been suggested that the hsp90
multi-protein complex differs between tumor cells and normal cells
and that this would result in increased drug access to the Hsp90
ATP binding sites. To date over 20 different Hsp90 inhibitors have
passed pre-clinical toxicity studies and advanced into phase I
clinical trials [85].
Our studies went beyond the first generation 17-DMAG/17-
AAG/geldanamycin structural class of hsp90 inhibitors and
evaluated four new, fully synthetic, chemically distinct ATP-
competitive inhibitors: PU-H71, AUY922, BIIB021, BEP800. All
inhibited KS and PEL tumor growth at low nanomolar
concentrations and all decreased the levels of other, known
Hsp90 client proteins such as cdc2 and Akt [5]. Whereas all PEL
were susceptible to Hsp90 inhibitors, we did observe cell line
variation. This is expected since these PEL cell lines have
accumulated both common and cell line specific genomic
alterations [68]. We and others observed similar alterations to
other targeted drugs previously [51,64,67,69], some of the variation
could be explained by p53 status, other drug-specific variation has
yet to be identified. This is a common effect seen in almost all studies
that use panels of cell lines rather than a single cell line as read-out.
AUY922 had the lowest IC50 (2 nM) against a battery of KS cell
lines. It is a product of structure-guided optimization of 4, 5-
diarylisoxazole compounds, which block the ATP-binding pocket of
Hsp90 [54,86]. AUY922 inhibited a tumor growth in a xenograft
KSHV tumor model with similar efficacy as reported previously for
other anti-KS compounds [54]. Recent studies have demonstrated
that, as a small-molecule inhibitor, AUY922 exhibits promising
therapeutic potential in a variety of cancers as such as lung cancer,
glioblastoma, myeloma, etc. [59,60,61,63]. KS and PEL can now be
added to the list and should be included in early-phase clinical
explorations of this compound.
It is likely that the pronounced anti-tumor effect of Hsp90
inhibitors is due to the downregulation of multiple targets: LANA,
which is essential for viral maintenance [17], cdc2, Akt, which
transduces paracrine and autocrine growth signals in PEL, KS and
other cancers [51], NFkB activators [15], ephrin-B2, and EphA2,
which support KSHV re-infection of endothelial cells and thus
tumor maintenance and even targets of surface bound Hsp90 [16].
Ephrins and Ephrin receptors are key molecules in endothelial
cell proliferation, tumorigenesis, and essential co-factors for
KSHV infection [34,35]. Ephrin receptor tyrosine kinases and
induce G0/G1 arrest of L1T2 cells. L1T2 cells were treated with 0.5 mM of 17-DMAG, PU-H71, NVP-BEP800, BIB021, or 0.05 mM AUY922 for 24 hours,
DMSO treatment was used as control. After cells were fixed and stained with propidium iodide, cell-cycle analysis was performed using flow
cytometry. The percentages of cells at different stages in the cell cycle (G0/G1, S, G2/M) are shown. (C) Growth curves of tumor volume. 105 L1T2 cells
were injected sub-cutaneously into C.B.-17 SCID mice with mixed Matrigel (1:1) for three days, followed by AUY922 intra-peritoneal injection at doses
of 50 mg/kg NVP-AUY922 for total three weeks (three times per week), tumor volumes of SCID mice were measured and analyzed. Two groups were
analyzed and each group had six mice, mock-treated mice were used as control.
doi:10.1371/journal.ppat.1003048.g009
Table 3. IC50 based on Xcelligence measurements of cell
proliferation.
Drug/Cell 17-DMAG PU-H71 AUY 922 BIIB021
NVP-
BEP800
L1T2 1963 2268 260.2 2964 9368
KS-KMM 1568 3069 261 2069 13865
SLK 5562 81610 462 5465 247629
SLK- KSHV 1165 60.1 0.560.2 2963 57612
Ratio SLK-
KSHV/SLK
3.3…9.56 4.2…5.36 2.8…206 1.5…2.36 3.2…6.26
All concentrations are in nM and the result of a titration series with 7 drug
concentrations each in n = 2 individual titration experiments. Also shown is the
range of ratios for IC50s for SLK compared to isogenic SLK-KSHV cells. This can
be interpreted as a selectivity index of KSHV positive compared to KSHV
negative cells.
doi:10.1371/journal.ppat.1003048.t003
HSP90 in Kaposi Sarcoma
PLOS Pathogens | www.plospathogens.org 14 November 2012 | Volume 8 | Issue 11 | e1003048
their ephrin ligands transduce signals in cell-cell contact-depen-
dent fashion. Their expression in endothelial cells promotes
angiogenesis [18,87,88]. We found two different molecules in this
network to be client proteins of Hsp90 in KS: EphA2 and ephrin-
B2 The EphA2 receptor kinase was previously identified as an
Hsp90 client [29,30]. Our studies showed that EphA2 was
expressed abundantly in L1T2, SLK-KSHV, and KS-IMM cells
and that Hsp90 inhibitors reduced EphA2 expression. Ephrin-B2
also plays multiple roles in vessel maturation, and is expressed at
substantial levels in KS [19], as well as in the KS tumor models we
examined in this study. Infection of endothelial cells with KSHV
induces expression of Ephrin-B2, and Ephrin B2 is required for
KS survival [19]. Blockage of Ephrin-B2 signaling with the
extracellular domain of EphB4 fused with human serum albumin
(sEphB4-HSA), suppressed a wide variety of tumors including KS
[19,20,31,89,90]. We found that Hsp90 inhibitors significantly
decreased the expression of Ephrin-B2 in multiple KS tumor
models (L1T2, SLK-KSHV), which suggests that downregulation
of ephrin interactions through Hsp90 inhibitors contributes to
their effectiveness in the endothelial lineage tumor KS.
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